-- Reported unprecedented, statistically significant reversal of compensated cirrhosis (F4) due to MASH after 96 weeks of treatment with efruxifermin (EFX) in Phase 2b SYMMETRY study --
-- Completed enrollment of the double-blinded portion of the Phase 3 SYNCHRONY Real-World Study evaluating EFX in patients with either MASLD or MASH --
Comments